A REVIEW ON APPROACHES USED TO OVERCOME PROBLEMS ASSOCIATED WITH CONVENTIONAL DOSAGE FORMS OF H2 ANTAGONIST

Mahalaxmi Rathnanand

Abstract

Gastro intestinal disease conditions includes acid reflux, heartburn, gastroesophageal reflux disease, dyspepsia, nausea and vomiting, peptic ulcer, abdominal pain, belching, swollen mucosal membrane with gastric fluids, the accumulation of gas in the alimentary canal, biliary tract and gallbladder infection. All these disorders are results of distinctive causes. Overlapping mechanism results in excessive acid secretion and diminished mucous defence. H2 antagonists generally most widely used in treatment of above conditions. Proton pump inhibitors shows therapeutic advances due to inhibition of most potent acid secretion. Neuronal stimulation and hormonal stimulation of receptor on basolateral and parietal membrane is modified by gastric HCl secretion. Cimetidine, ranitidine, famotidine, and nizatidine have been used to treat these conditions which act on H2 receptor. They are structural analogues of H2 receptor that causes decrease tonic activation rate of the receptor. H2 antagonists have disadvantages like handling, bitterness, moisture absorption, gastric emptying. This review mainly focuses on methods to improve problems related to H2 antagonists.

Full Text:

PDF

References

Tripathi KD. Drugs for peptic ulcer. In: Tripathi M, editor. Essential of Medicinal Pharmacology. New Delhi: Jaypee Brothers Medical Publisher, 2008. P. 627-51.

Pension J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Medical Toxicology. 1986 Jun 1;1(3):192-216.

Lipsy RJ, Fennerty B, Fagan TC. Clinical review of histamine2 receptor antagonists. Archives of internal medicine. 1990 Apr 1;150 (4):745-51.

https://www.drugs.com/drug-class/h2-antagonists.html

Rakesh P, Shilpa S, Vipin K, Kanchan K. Ranitidine hydrochloride: An update on analytical, clinical and pharmacological aspects. J. Chem. Pharm. Res., 2016, 8(7):70-78.

Brimblecombe RW, Duncan WA, Durant GJ, Emmett JC, Ganellin CR, Leslie GB, Parsons ME. Characterization and development of cimetidine as a histamine H2-receptor antagonist. Gastroenterology. 1978 Feb 1;74(2):339-47.

Scheinfeld N. Cimetidine: a review of the recent developments and reports in cutaneous medicine. Dermatology online journal. 2003 Jan 1;9(2).

Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT. Famotidine, a new, potent, long-acting histamine H 2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr 30;88(4):1026-33.

Basavaiah K, Nagegowda P, Ramakrishna V. Determination of drug content of pharmaceuticals containing ranitidine by titrimetry and spectrophotometry in non-aqueous medium. Sci Asia. 2005;31:207-14.

Kumar AR, Katz PO. Functional esophageal disorders: a review of diagnosis and management. Expert review of gastroenterology & hepatology. 2013 Jul 1.

Basit AW, Lacey LF. Colonic metabolism of ranitidine: implications for its delivery and absorption. International journal of pharmaceutics. 2001 Oct 4;227(1):157-65.

Williams MF, Dukes GE, Heizer W, Han YH, Hermann DJ, Lampkin T, Hak LJ. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. Pharmaceutical research. 1992 Sep 1;9(9):1190-4.

Gladziwa U, Wagner S, Sieberth HG, Klotz U. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency. British journal of clinical pharmacology. 1995 Feb 1;39(2):161-7.

https://en.wikipedia.org/wiki/Roxatidine_acetate

Gomes AR, Raghuram P, Sriramulu J, Srinivas N. Rapid validated stability indicating method for nizatidine and its impurities quantification. American Journal of Analytical Chemistry. 2011 Jul 1;2(03):314.

. Garg RK, Singhvi I. UV Spectrophotometric Method Development and Validation for quantitative estimation of Nizatidine.

Hassan EM, Belal F. Kinetic spectrophotometric determination of nizatidine and ranitidine in pharmaceutical preparations. Journal of pharmaceutical and biomedical analysis. 2002 Jan 1;27(1):31-8.

Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Clinical pharmacokinetics. 1991 Mar 1;20(3):218-36.

Aman RM, Meshali MM, Abdelghani GM. Ion-exchange complex of famotidine: sustained release and taste masking approach of stable liquid dosage form. Drug discoveries & therapeutics. 2014 Dec 31;8(6):268-75.

Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Clinical pharmacokinetics. 1991 Mar 1;20(3):218-36.

Eshelman FN, Plachetka JR, Brown DC. Bioavailability and tolerance of repeated intramuscular injections of ranitidine. InCLINICAL PHARMACOLOGY & THERAPEUTICS 1983 Jan 1 (Vol. 33, No. 2, pp. 251-251). 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318: MOSBY-YEAR BOOK INC.

Walkenstein SS, Dubb JW, Randolph WC, Westlake WJ, Stote RM, Intoccia AP. Bioavailability of cimetidine in man. Gastroenterology. 1978 Feb 1;74(2):360-5.

https://www.medicineindia.org/pharmacology-for-generic/1341/roxatidine

http://www.medindia.net/drug-price/cimetidine.htm

http://www.medindia.net/drug-price/ranitidine.htm

http://www.medindia.net/drug-price/famotidine.htm

http://www.medindia.net/drug-price/roxatidine.htm

Kunin R. Amber-hi-lites: Fifty Years of Ion-exchange Technology. Tall Oaks Publishing; 1996.

Mangesh B, Patil G, Maria S, Zhaheed Z, Aney J. A Method for Improving Handling Properties of Ranitidine HCl. Journal of Pharmaceutical Research. 2009 Apr 1;8(2):112-5.

Sastry SV, Nyshadham JR, Fıx JA. Recent technological advances in oral drug delivery. A review. Pharm Sci Technol Today 2000; 3(4):138–145.

Seager H. Drug‐delivery products and the Zydis fast‐dissolving dosage form. Journal of pharmacy and pharmacology. 1998 Apr 1;50(4):375-82.

Bently O, Rawlins EA, Bently’s Text Book of Pharmaceutics, 8th Edition, Bailliere Tindall, UK, 1984, pp. 147-148

Nakabayashi K, Shimamoto T, Mima H. Stability of packaged solid dosage forms. Ii. Shelf-life prediction for packaged sugar-coated tablets liable to moisture and heat damage. Chemical and pharmaceutical bulletin. 1980 apr 25;28(4):1099-106.

Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. Journal of Controlled release. 2000 Feb 3;63(3):235-59.

Nonaka T, Kessoku T, Ogawa Y, Imajyo K, Yanagisawa S, Shiba T, Sakaguchi T, Atsukawa K, Takahashi H, Sekino Y, Sakai E. Effects of histamine-2 receptor antagonists and proton pump inhibitors on the rate of gastric emptying: a crossover study using a continuous real-time 13C breath test (BreathID system). Journal of neurogastroenterology and motility. 2011 Jul;17(3):287.

Anand V, Kandarapu R, Garg S. Ion-exchange resins: carrying drug delivery forward. Drug Discovery Today. 2001 Sep 1;6(17):905-14

Islam SA, Hossain MA, Kabir AH, Kabir S, Hossain MK. Study of moisture absorption by ranitidine hydrochloride: effect of% RH, excipients, dosage forms and packing materials. Dhaka University Journal of Pharmaceutical Sciences. 2008;7(1):59-64

Nakabayashi K, Shimamoto T, Mima H. Stability of packaged solid dosage forms. Ii. Shelf-life prediction for packaged sugar-coated tablets liable to moisture and heat damage. Chemical and pharmaceutical bulletin. 1980 apr 25;28(4):1099-106.

Khan S, Giradkar P, Nakhat P, Yeole P. Effects of Weak and Strong Cation Exchange Resins on Moisture Uptake Behavior of Ranitidine Hydrochloride. Iranian Journal of Pharmaceutical Sciences. 2007 Jan 1;3(1):31-6.

Mizumoto T, Tamura T, Kawai H, Kajiyama A, Itai S. Formulation design of taste-masked particles, including famotidine, for an oral fast-disintegrating dosage form. Chemical and Pharmaceutical Bulletin. 2008 Apr 1;56(4):530-5.

Sugao H, Yamazaki S, Shiozawa H, Yano K. Taste masking of bitter drug powder without loss of bioavailability by heat treatment of wax‐coated microparticles. Journal of pharmaceutical sciences. 1998 Jan 1;87(1):96-100.

Funasaki N, Uratsuji I, Okuno T, Hirota S, Neya S. Masking mechanisms of bitter taste of drugs studied with ion selective electrodes. Chemical and pharmaceutical bulletin. 2006;54(8):1155-61.

Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. Journal of Controlled release. 2000 Feb 3;63(3):235-59.

Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. Aaps PharmSciTech. 2005 Sep 1;6(3): E372-90.

Rohith G, Sridhar B, Srinatha A. Floating drug delivery of a locally acting H2-antagonist: An approach using an in situ gelling liquid formulation. Acta pharmaceutical. 2009 Sep 1;59(3):345-54.

Refbacks

  • There are currently no refbacks.


Bookmark and Share